Hormone Therapy Increases Odds of Ovarian Cancer
However, Wyeth, maker of two conjugated estrogens -- Premarin and Prempro -- said the study didn't have enough women taking conjugated estrogens to determine actual risk for that type of hormone therapy.
"The findings in this study do not change what we already know about the benefits and risks of hormone therapy, which is based on data from multiple studies. Hormone therapy remains a good health-care choice for the appropriate woman seeking relief from moderate to severe menopausal symptoms," said a prepared statement from Wyeth.
"Biologically, the ovaries are intended to be in retirement after a certain age. If you try to restimulate them, it shouldn't be surprising that there are potential adverse consequences," said Dr. Victor Vogel, national vice president of research for the American Cancer Society.
"From an epidemiological standpoint, this is important, but for an individual woman, what's likely is that she'll never develop ovarian cancer," he said.
Add A New Comment
Add A New CommentComments
There are no comments yet. Be the first to get the conversation started.